Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/3/2020
SIETES contiene 92954 citas

 
 
 1 a 20 de 222 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Chambers HF. Omadacycline — The newest tetracycline. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103037]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103036]
4.Enlace a cita original Cita con resumen
Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, Steele MT, Rothman RE, Hoagland R, Moran GJ. Trimethoprim–sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med 2016;374:3 de marzo. [Ref.ID 100027]
5. Cita con resumen
Anónimo. Télavancine. Prescrire 2015;35:335-8. [Ref.ID 99134]
6.Tiene citas relacionadas
Wessels MR. Choosing an antibiotic for skin infections. N Engl J Med 2015;372:1164-5. [Ref.ID 98962]
7.Tiene citas relacionadas Cita con resumen
Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF, DMID 07-0051 Team. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015;372:1093-103. [Ref.ID 98961]
8. Cita con resumen
Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru J-P, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D, on behalf of the Duration of Treatment for Spondylodiscitis (DTS) study group. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 2015;385:875-82. [Ref.ID 98935]
9. Cita con resumen
Anónimo. Newly discovered antibiotic may combat drug-resistant bacteria. DIA Daily 2015:8 de enero. [Ref.ID 98700]
10. Cita con resumen
Anónimo. Oritavancin (Orbactiv) for skin and skin structure infections. Med Lett Drugs Ther 2015;57:3-5. [Ref.ID 98698]
11. Cita con resumen
Bowen AC, Tong SY, Andrews RM, O'Meara IM, McDonald MI, Chatfield MD, Currie BJ, Carapetis JR. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet 2014;384:2132-40. [Ref.ID 98455]
12. Cita con resumen
Anónimo. FDA approves Orbactiv to treat skin infections. U.S. Food and Drug Administration 2014:6 de agosto. [Ref.ID 97853]
13. Cita con resumen
Anónimo. Drugs for MRSA skin and soft-tissue infections. Med Lett Drugs Ther 2014;56:39-40. [Ref.ID 97620]
14. Cita con resumen
Anónimo. New antibiotic for skin infections gets FDA nod. DIA Daily 2014:27 de mayo. [Ref.ID 97585]
15. Cita con resumen
Cherian P, Gunsson T, Borchard K, Tai Y, Smith H, Vinciullo C. Oral antibiotics versus topical decolonization to prevent surgical site infection after Mohs micrographic surgery - a randomized, controlled trial. Dermatologic surgery 2013;39:1486. [Ref.ID 96705]
18.Tiene citas relacionadas
Edmond MB, Wenzel RP. Screening inpatients for MRSA - Case closed. N Engl J Med 2013;368:2314-5. [Ref.ID 95552]
19.Tiene citas relacionadas Cita con resumen
Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R, the CDC Prevention Epicenters Program: the AHRQ DECIDE Network and Healthcare-Associated Infections Program. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013;368:2255-65. [Ref.ID 95550]
20.Tiene citas relacionadas
Seleccionar todas
 
 1 a 20 de 222 siguiente >>